The Latest Breaking News from Influenza

Cidara Therapeutics, Inc. (NASDAQ:CDTX) shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic influenza therapeutic and onshore its manufacturing.

Live Science spoke with leading epidemiologist Michael Osterholm about his new book, "The Big One," which discusses the next pandemic and how to mitigate its harm.

Girl was sent home from Sydney Children’s hospital in Randwick twice before being admitted to Northern Beaches hospital a day later, where she died

The Health and Human Services secretary once again stands athwart biomedical progress yelling, "Stop!"

Scientists fear decision may increase vaccine hesitancy, but other countries are still willing to invest in research

Millions of people who recover from infections like COVID-19, influenza and glandular fever are affected by long-lasting symptoms. These include chronic fatigue, brain fog, exercise intolerance, dizziness, muscle or joint pain and gut problems. And many of these symptoms worsen after exercise, a phenomenon known as post-exertional malaise.

Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate.

Moderna Inc.’s (NASDAQ:MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date.

Winter is here, and with it come higher rates of respiratory illnesses. If you’ve been struck down recently with a sore throat, runny nose and a cough, or perhaps even a fever, you’re not alone.